Next Article in Journal
Lactobacillus casei Strain Shirota Enhances the In Vitro Antiproliferative Effect of Geniposide in Human Oral Squamous Carcinoma HSC-3 Cells
Next Article in Special Issue
Network Medicine for Alzheimer’s Disease and Traditional Chinese Medicine
Previous Article in Journal
Xanthones Content in Swertia multicaulis D. Don from Nepal
Previous Article in Special Issue
Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessFeature PaperReview
Molecules 2018, 23(5), 1068;

Passive Aβ Immunotherapy: Current Achievements and Future Perspectives

Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, 06120 Halle (Saale), Germany
Probiodrug AG, 06120 Halle (Saale), Germany
Ann Romney Center for Neurologic Diseases, Brigham and Womens’s Hospital, Harvard Medical School, Boston, MA 02116, USA
Author to whom correspondence should be addressed.
Received: 29 March 2018 / Revised: 23 April 2018 / Accepted: 25 April 2018 / Published: 3 May 2018
(This article belongs to the Special Issue 25th Anniversary of the Amyloid Hypothesis and Alzheimer Disease)
Full-Text   |   PDF [512 KB, uploaded 3 May 2018]   |  


Passive immunotherapy has emerged as a very promising approach for the treatment of Alzheimer’s disease and other neurodegenerative disorders, which are characterized by the misfolding and deposition of amyloid peptides. On the basis of the amyloid hypothesis, the majority of antibodies in clinical development are directed against amyloid β (Aβ), the primary amyloid component in extracellular plaques. This review focuses on the current status of Aβ antibodies in clinical development, including their characteristics and challenges that came up in clinical trials with these new biological entities (NBEs). Emphasis is placed on the current view of common side effects observed with passive immunotherapy, so-called amyloid-related imaging abnormalities (ARIAs), and potential ways to overcome this issue. Among these new ideas, a special focus is placed on molecules that are directed against post-translationally modified variants of the Aβ peptide, an emerging approach for development of new antibody molecules. View Full-Text
Keywords: amyloid-β; monoclonal antibodies; posttranslational modifications; drug development amyloid-β; monoclonal antibodies; posttranslational modifications; drug development

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Schilling, S.; Rahfeld, J.-U.; Lues, I.; Lemere, C.A. Passive Aβ Immunotherapy: Current Achievements and Future Perspectives. Molecules 2018, 23, 1068.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top